Clare Arnott - Concepedia

Author

Clare Arnott

The George Institute for Global Health ORCID

Also Known As

Arnott, C, Arnott, Clare, C Arnott, C. Arnott, CLARE ARNOTT, Christopher Arnott, Clare Arnott, Clare G. Arnott, Clare Gabrielle Arnott, Dominica Zentner

218

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

The George Institute for Global Health Royal Prince Alfred Hospital UNSW Sydney The University of Sydney Stanford University

About

Clare Arnott is an author at The George Institute for Global Health specializing in medicine, cardiology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	899
2	Public Health	5	5	439
3	Emergency Medicine	4	4	75
4	Health Sciences	1	1	11
5	Cardiothoracic Surgery	1	1	11

Clare Arnott

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data Gemma A. Figtree, Stephen T. Vernon, Nermin Hadziosmanovic, The Lancet Preventive MedicineCardiovascular EpidemiologyHealth PolicyEpidemiological OutcomeSex-disaggregated Analysis	2021	290
Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome Kaivan Vaidya, Clare Arnott, Gonzalo J. Martínez, JACC. Cardiovascular imaging ThrombosisColchicine TherapyCardiovascular DiseaseAtherosclerosisPharmacology	2017	284
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, Circulation	2023	252
Colchicine in Cardiovascular Disease: In-Depth Review. Spyridon Deftereos, Frans Beerkens, Binita Shah, PubMed	2022	135
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes Jingwei Li, Bruce Neal, Vlado Perkovic, Kidney International	2020	126
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial Brendon L. Neuen, Megumi Oshima, Vlado Perkovic, European Heart Journal	2021	118
Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China Shijun Xia, Xin Du, Lizhu Guo, Circulation	2020	117
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease Nan Ye, Meg Jardine, Megumi Oshima, Circulation	2021	110
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial Taha Sen, Jingwei Li, Brendon L. Neuen, Diabetologia	2021	80
Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial Jie Yu, Sudhir Raj Thout, Qiang Li, American Journal of Clinical Nutrition HypertensionHealth PolicyCardiovascular DiseaseSodium HomeostasisAntihypertensive Therapy	2021	75

Page 1